1. Ariyoshi, K., Matsuda, M., Miura, H., Tateishi, S., Yamada, K. & Sugiura, W. (2003) Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune Defic. Syndr., 33, 336-342.
2. Bennett, D.E., Bertagnolio, S., Sutherland, D. & Gilks, C.F. (2008) The World Health Organization’s global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther., 13 Suppl 2, 1-13.
3. Chen, M., Wang, J., Xing, H., Ma, Y., Yao, S., Chen, H., Yang, J., Li, Y., Duan, S. & Jia, M. (2014) Study on HIV-1 related genetics and threshold on drug resistance in Dehong prefecture of Yunnan province in 2012. Zhonghua Liu Xing Bing Xue Za Zhi, 35, 909-912.
4. Chen, Z.W., Liu, L., Chen, G., Cheung, K.W., Du, Y., Yao, X., Lu, Y., Chen, L., Lin, X. & Chen, Z. (2018) Surging HIV-1 CRF07_BC epidemic among recently infected men who have sex with men in Fujian, China. J. Med. Virol., 90, 1210-1221.
5. Clevenbergh, P., Durant, J., Halfon, P., del Giudice, P., Mondain, V., Montagne, N., Schapiro, J.M., Boucher, C.A. & Dellamonica, P. (2000) Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir. Ther., 5, 65-70.